Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Salarius Pharmaceuticals Inc (SLRX)

Salarius Pharmaceuticals Inc (SLRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,943
  • Shares Outstanding, K 56,116
  • Annual Sales, $ 1,840 K
  • Annual Income, $ -12,770 K
  • 60-Month Beta 1.44
  • Price/Sales 6.34
  • Price/Cash Flow N/A
  • Price/Book 0.35
Trade SLRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.37
  • Most Recent Earnings -0.13 on 05/12/22
  • Next Earnings Date 08/04/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.07
  • Growth Rate Est. (year over year) -57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1662 +17.33%
on 05/25/22
0.2386 -18.27%
on 06/15/22
+0.0175 (+9.86%)
since 05/24/22
3-Month
0.1599 +21.95%
on 05/24/22
0.4440 -56.08%
on 03/30/22
-0.2110 (-51.97%)
since 03/24/22
52-Week
0.1599 +21.95%
on 05/24/22
1.2000 -83.75%
on 09/24/21
-0.8850 (-81.94%)
since 06/24/21

Most Recent Stories

More News
Salarius Pharmaceuticals to Participate in BIO International Convention 2022

HOUSTON, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing...

SLRX : 0.1950 (-6.16%)
Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

HOUSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential...

SLRX : 0.1950 (-6.16%)
Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results

Salarius Successfully Completes SP-3164 Pre-IND Meeting Process with FDA Advancing multiple drug development programs, led by SP-3164 in targeted protein...

SLRX : 0.1950 (-6.16%)
Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius planning for SP-3164 IND Application Submission in 2023...

SLRX : 0.1950 (-6.16%)
Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress

Conference Call and Live Audio Webcast Scheduled for Thursday, May 12, 2022, 5:00 p.m. ET...

SLRX : 0.1950 (-6.16%)
Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering

HOUSTON, April 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing cancer...

SLRX : 0.1950 (-6.16%)
Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results

Strategic acquisition of SP-3164, a targeted protein degrader in development for hematologic and solid tumors, adds to pipeline of cancer therapies ...

SLRX : 0.1950 (-6.16%)
Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress

Conference Call and Live Audio Webcast Scheduled for Thursday, March 10, 2022, 5:00 p.m. ET...

SLRX : 0.1950 (-6.16%)
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference

HOUSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential...

SLRX : 0.1950 (-6.16%)
Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Dr. Santiesteban will lead the development of SP-3164 and other targeted protein degradation assets...

SLRX : 0.1950 (-6.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Salarius Pharmaceuticals Inc. is a clinical-stage oncology company. It develops therapies for the treatment of cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and...

See More

Key Turning Points

3rd Resistance Point 0.2430
2nd Resistance Point 0.2334
1st Resistance Point 0.2142
Last Price 0.1950
1st Support Level 0.1854
2nd Support Level 0.1758
3rd Support Level 0.1566

See More

52-Week High 1.2000
Fibonacci 61.8% 0.8027
Fibonacci 50% 0.6799
Fibonacci 38.2% 0.5572
Last Price 0.1950
52-Week Low 0.1599

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar